Cantor Fitzgerald Maintains a 'Hold' on Life Technologies (LIFE); Chance to Outshine Illumina? External Validation Still Needed
Tweet
Share
E-mailGet Alerts LIFE Hot Sheet
Price: $1.62 +1.89%
Rating Summary:
6 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 5
Rating Summary:
6 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 5
Join SI Premium – FREE
Cantor Fitzgerald maintains a 'Hold' on Life Technologies (NASDAQ: LIFE) price target of $45.00.
Cantor analyst says, "Last night, LIFE announced the launch of the new benchtop Ion Proton Sequencer, which the company believes will be able to sequence an entire human genome for <$1,000 in under a day by the end of 2012. Not to be confused with the Ion PGM, the new platform has not been publicly discussed in earnest before, and could be gamechanging in that the current industry-leading platform (Illumina's HiSeq (NASDAQ: ILMN)(HOLD)) takes ~11 days to sequence one human genome (in a batch of five) for ~$2.5K."
"While the technology sounds impressive on paper, we look for early user feedback before turning more constructive on LIFE and Illumina (Nasdaq: ILMN). Particularly, with a potentially game-changing platform at hand, we are curious as to why LIFE is positioning the new platform as complementary to its existing sequencing portfolio and not as possibly displacing at least one or even more of the current systems. LIFE expects to provide 2012 guidance, including the impact from the new sequencer, in February."
For an analyst ratings summary and ratings history on Life Technologies click here. For more ratings news on Life Technologies click here.
Shares of Life Technologies closed at $42.65 yesterday.
Cantor analyst says, "Last night, LIFE announced the launch of the new benchtop Ion Proton Sequencer, which the company believes will be able to sequence an entire human genome for <$1,000 in under a day by the end of 2012. Not to be confused with the Ion PGM, the new platform has not been publicly discussed in earnest before, and could be gamechanging in that the current industry-leading platform (Illumina's HiSeq (NASDAQ: ILMN)(HOLD)) takes ~11 days to sequence one human genome (in a batch of five) for ~$2.5K."
"While the technology sounds impressive on paper, we look for early user feedback before turning more constructive on LIFE and Illumina (Nasdaq: ILMN). Particularly, with a potentially game-changing platform at hand, we are curious as to why LIFE is positioning the new platform as complementary to its existing sequencing portfolio and not as possibly displacing at least one or even more of the current systems. LIFE expects to provide 2012 guidance, including the impact from the new sequencer, in February."
For an analyst ratings summary and ratings history on Life Technologies click here. For more ratings news on Life Technologies click here.
Shares of Life Technologies closed at $42.65 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades ULTA Salon (ULTA) to Hold, 'Competition Intensifying & Prestige Refresh Needed'
- Itau BBA Reiterates Outperform Rating on WEG S.A. (WEGE3:BZ) (WEGZY)
- Boston Beer Company (SAM) PT Lowered to $310 at Evercore ISI
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
